Table 1 . Characteristics of the Selected Studies in the Systematic Review and Effectiveness of Heparin and Taurolidine-Citrate Based on Three Outcomes .
| Study | Arms of study | Number of patients | Average of Patients Age | Dose & Route of Treatment | Effectiveness | ||
|
CRB eEpisode (Incidence n(%)) |
CRB-Free Catheter Survival (cumulative CRB-free catheter survival at 90 days) |
Catheter Thrombosis rate N (%) |
|||||
|
Filiopoulos V, et al., 2011 |
(A): Gentamicin/heparin- (B): Taurolidine/citrate (C): Heparin |
60-59-58 |
(A): 72 (50-80) (B): 75 (36-95) (C): 70 (42-84) |
(A): 40 mg/ml gentamicin and 5,000 U/ml unfractionated heparin; ratio 1:3 (B):1.35% taurolidine and 4% sodium citrate; TauroLock TM , TauroPharm GmbH (c): heparin 5,000 U/ml |
(A): 6(10%); (B): 8(13.5%) (C): 20(34.48) ***************** (A) vs (C): χ²= 6.62, p= 0.01 (B) vs (C): χ²= 4.34, p= 0.03. (A) vs (B): N sig |
(A): 82% (B): 78% (C): 26% ************ (A) vs (C): log-rank 3.03, p= 0.002 (B) vs (c):log-rank 2.63, p= 0.008 (A) vs (B): N sig |
(A): 11 (14.86%) (B): 9 (11.84%) (C): 6 (8.95%) ************ A) vs (B):χ²= 0.23, p= 0.63: N sig (A) vs (C): χ²= 0.91, p= 0.33: N sig (B) vs (c):χ²= 0.26, p= 0.61: N sig |
|
Solomon LR, et al., 2010 |
(A): Taurolidine/citrate (B): Heparin |
53-54 |
)A): 59.8±14.7 (B): 56.7±17.4 |
(A):1.35% taurolidine and 4% citrate (B): Heparin (5,000 U/mL) |
(A):9 (17%) (B): 16 (30%) ************* p=0.1: (A) vs (B): N sig |
Not reported |
(A): 28 (53%) (B): 14 (26%) *************** p= 0.006; significant |
|
Betjes MGH, et al., 2004 |
(A): Taurolidine/citrate (B): Heparin |
28-28 |
(A): 58.3±16.3 (B): 50.3±20.4 |
(A):1.35% taurolidine and 4% citrate; (B): Heparin (5,000 U/mL) |
(A):0 (B): 4 (14%) **************** p= not reported |
the sepsis-free survival was significantly lower in patients [B] compared with [A] group (p= 0.047) | Not reported |